High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: Prognostic features and outcomes

References

• Lasker S, Gupta T, Vimal S, Muckaden M A, Saikia T K, Pai S K, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. J Clin Oncol 2004; 22: 62–68
   PubMed Web of Science ®Google Scholar
• Strauss D J, Portlock C S, Qin J, Myers J, Zelenetz A D, Moskowitz C, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIa nonbulky Hodgkin disease. Blood 2004; 104: 3483–3489
   PubMed Web of Science ®Google Scholar
• Meyer R M, Gospodarowicz M K, Connors J M, Pearcey R G, Bezjak A, Wells W A, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634–4642
   PubMed Web of Science ®Google Scholar
• Canellos G P, Anderson J R, Propert K J, Nissen N, Cooper M R, Henderson E, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Duggan D B, Petroni G R, Johnson J L, Glick J H, Fisher R I, Connors J M, et al. Randomized comparison of ABVD and MOPP/ABV for the treatment of advanced Hodgkin's disease: report of an Intergroup Trial. J Clin Oncol 2003; 21: 607–614
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V, Armitage J O, Assouline D, Björkholm M, Brusamolino E, et al. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta J J, Garcia-Conde J, et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404
   PubMed Web of Science ®Google Scholar
• Fermé C, Mounier N, Diviné M, Brice P, Stamatoullas A, Reman O, et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Études des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467–475
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Brice P, Brugiatelli M, Nagler A, Gisselbrecht C, et al. High-dose therapy and autologus stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003; 21: 2320–2325
   PubMed Web of Science ®Google Scholar
• Gribben J G, Linch D C, Singer C R, McMillan A K, Jarrett M, Goldstone A H. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340–344
   PubMed Web of Science ®Google Scholar
• Kessinger A, Bierman P J, Vose J M, Armitage J O. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 77: 2322–2325
   PubMed Web of Science ®Google Scholar
• Lavoie J C, Connors J M, Phillips G L, Reece D E, Barnett M J, Forrest D L, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005; 106: 1473–1478
   PubMed Web of Science ®Google Scholar
• Reece D E, Barnett M J, Shepherd J D, Hogge D E, Klasa R J, Nantel S H, et al. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451–456
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, Sieber M, Carella A M, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomized trial. Lancet 2002; 359: 2065–2071
   PubMed Web of Science ®Google Scholar
• Sweetenham J W, Taghipour G, Milligan D, Blystad A K, Caballero D, Fassas A, et al. High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 745–752
   PubMed Web of Science ®Google Scholar
• Yuen A R, Rosenberg S A, Hoppe R T, Halpern J D, Horning S J. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814–822
   PubMed Web of Science ®Google Scholar
• Bierman P J, Lynch J C, Bociek R G, Whalen V L, Kessinger A, Vose J M. The International Prognostic Factors Project scare for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation. Ann Oncol 2002; 13: 1370–1377
   PubMed Web of Science ®Google Scholar
• Brice P, Bouabdallah R, Moreau P, Divine M, Andre M, Aoudjane M, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Bone Marrow Transplant 1997; 20: 21–26
   PubMed Web of Science ®Google Scholar
• Hahn T, Benekli M, Wong C, Moysich K B, Hyland A, Michalek A M, et al. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 2005; 35: 557–566
   PubMed Web of Science ®Google Scholar
• Horning S J, Chao N J, Negrin R S, Hoppe R T, Long G D, Hu W W, et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University Results and Prognostic Indices. Blood 1997; 89: 801–813
   PubMed Web of Science ®Google Scholar
• Moskowitz C H, Nimer S D, Zelenetz A D, Trippett T, Hedrick E E, Filippa D A, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program fro relapsed and refractory Hodgkin's disease: analysis by intent to treat and development of a prognostic model. Blood 2000; 97: 616–623
   Web of Science ®Google Scholar
• Reece D E, Connors J M, Spinelli J J, Barnett M J, Fairey R N, Klingemann H G, et al. Intensive Therapy with Cyclophosphamide, Carmustine (BCNU), and Etoposide ± Cisplatin and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193–1199
   PubMed Web of Science ®Google Scholar
• Lister T A, Crowther D, Sutcliffe S B, Glatstein E, Canellos G P, Young R C, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630–1636
   PubMed Web of Science ®Google Scholar
• Moritabo F, Stelitano C, Luminari S, Mammi C, Marcheselli L, Callea V, et al. The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linformi (GISL). Bone Marrow Transplant 2006; 37: 283–288
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Diehl V, Thomas R K, Re D. Part II: Hodgkin's lymphoma – diagnosis and treatment. Lancet Oncol 2004; 5: 19–26
   PubMed Web of Science ®Google Scholar
• Elkstrand B C, Horning S J. Hodgkin's disease. Blood Rev 2002; 16: 111–117
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Maertens J, Bormans G, et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 2003; 102: 53–59
   PubMed Web of Science ®Google Scholar